TY  - GEN
AU  - Esquinas, Esperanza
AU  - Moreno-Sanz, Alvaro
AU  - Sandá, Victor
AU  - Stodulski-Ciesla, Damian
AU  - Borregón, Jennifer
AU  - Peña-Blanque, Virginia
AU  - Fernández-Calles, Javier
AU  - Fernandez-Fuentes, Narcis
AU  - Serrano-Lopez, Juana
AU  - Juan, Manel
AU  - Engel, Pablo
AU  - Llamas-Sillero, Pilar
AU  - Solán-Blanco, Laura
AU  - Martín-Antonio, Beatriz
PY  - 2024
DO  - 10.1136/jitc-2024-009485
UR  - https://hdl.handle.net/20.500.12105/26048
AB  - Background: Infusion of T cells modified with a chimeric antigen receptor (CAR) targeting CD19 has achieved exceptional responses in patients with non-Hodgkin's lymphoma (NHL), which led to the approval of CAR targeting CD19 (CART19) (Axi-cel and...
LA  - eng
PB  - BMJ Publishing Group
KW  - Chimeric antigen receptor - CAR
KW  - Lymphoma
KW  - T cell
KW  - Animals
KW  - Antigens, CD19
KW  - CD79 Antigens
KW  - Humans
KW  - Immunotherapy, Adoptive
KW  - Lymphoma, Non-Hodgkin
KW  - Mice
KW  - Receptors, Chimeric Antigen
TI  - Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin's lymphoma and characterization of the loss of the target antigen
TY  - research article
ER  -